Literature DB >> 25074626

Drug reaction with eosinophilia and systemic symptoms during primary Epstein-Barr virus infection.

Etsuro Nanishi1, Takayuki Hoshina2, Shouichi Ohga1, Hisanori Nishio1, Toshiro Hara1.   

Abstract

We report a drug reaction with eosinophilia and systemic symptoms case of primary Epstein-Barr virus (EBV) infection, in which the diagnosis was first confirmed by lymphocyte transformation tests (LTT). LTTs were positive for cefditoren-pivoxil and acetaminophen. LTT, EBV load, and anti-EBV antibodies could allow early diagnosis of drug reaction with eosinophilia and systemic symptoms, which masquerades with the clinical features of infectious mononucleosis.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  Epstein–Barr virus; acetaminophen; cefditoren–pivoxil; drug reaction with eosinophilia and systemic symptoms; lymphocyte transformation test

Mesh：

Substances：

Year:  2014        PMID： 25074626     DOI： 10.1016/j.jmii.2014.06.012

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN： 1684-1182            Impact factor:   4.399


  4 in total

1.  Lamotrigine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) during primary Epstein-Barr virus (EBV) infection.

Authors:  Ibrahim Tawhari; Fawaz Tawhari; Mossab Aljuaid
Journal:  BMJ Case Rep       Date:  2018-01-23

2.  Drug Reaction with Eosinophilia and Systemic Symptoms Associated with Reactivation of Epstein-Barr Virus and/or Cytomegalovirus Leading to Hemophagocytic Syndrome in One of Two Patients.

Authors:  Jianhua Liang; Hui Qu; Xiaowen Wang; Aiping Wang; Lingling Liu; Ping Tu; Ruoyu Li; Mingyue Wang
Journal:  Ann Dermatol       Date:  2017-12-26       Impact factor: 1.444

3.  Drug reaction with eosinophilia and systemic symptoms (DRESS) in children.

Authors:  Francesca Mori; Carlo Caffarelli; Silvia Caimmi; Paolo Bottau; Lucia Liotti; Fabrizio Franceschini; Fabio Cardinale; Roberto Bernardini; Giuseppe Crisafulli; Francesca Saretta; Elio Novembre
Journal:  Acta Biomed       Date:  2019-01-29

4.  A case of cefditoren-induced acute generalized exanthematous pustulosis during COVID-19 pandemics. Severe cutaneous adverse reactions are an issue.

Authors:  I Torres-Navarro; C Abril-Pérez; J Roca-Ginés; J Sánchez-Arráez; R Botella-Estrada
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-07-02       Impact factor: 9.228
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.